{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:29:52Z","timestamp":1789014592629,"version":"build-2803163510"},"reference-count":100,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Novartis, N\u00fcrnberg, Germany"},{"name":"Kompetenznetz f\u00fcr Akute und Chronische Leuk\u00e4mien"},{"name":"Deutsche Jos\u00e9-Carreras Leuk\u00e4miestiftung"},{"name":"European LeukemiaNet"},{"name":"Roche, Grenzach-Wyhlen"},{"name":"Germany and Essex Pharma, M\u00fcnchen, Germany"},{"name":"Cancer Research and Treatment Fund, Inc., New York, New York"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.beha.2016.10.005","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T14:50:33Z","timestamp":1476975033000},"page":"295-307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"title":["Management of CML-blast crisis"],"prefix":"10.1016","volume":"29","author":[{"given":"R\u00fcdiger","family":"Hehlmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Sau\u00dfele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astghik","family":"Voskanyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2016.10.005_bib1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000046636","article-title":"Cytogenetic and molecular genetic evolution of chronic myeloid leukemia","volume":"107","author":"Johansson","year":"2002","journal-title":"Acta Haematol"},{"key":"10.1016\/j.beha.2016.10.005_bib2","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib3","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","article-title":"How I treat CML blast crisis","volume":"120","author":"Hehlmann","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/ijc.2910180105","article-title":"Non-random karyotypic evolution in chronic myeloid leukemia","volume":"18","author":"Mitelman","year":"1976","journal-title":"Int J Cancer"},{"key":"10.1016\/j.beha.2016.10.005_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0165-4608(87)90131-2","article-title":"The karyotype of blastic crisis","volume":"26","author":"Alimena","year":"1987","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.beha.2016.10.005_bib6","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib7","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib8","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2016.6","article-title":"Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","author":"Chen","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.005_bib9","doi-asserted-by":"crossref","first-page":"e0129648","DOI":"10.1371\/journal.pone.0129648","article-title":"Clonal evolution and blast crisis correlate with enhanced proteolytic activity of separase in BCR-ABL b3a2 fusion type CML under imatinib therapy","volume":"10","author":"Haa\u00df","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.beha.2016.10.005_bib10","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1200\/JCO.2005.05.531","volume":"23","author":"Soverini","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.10.005_bib11","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood.V84.8.2391.2391","article-title":"Structure and function of p53 in normal cells and their aberrations in cancer cells: projection on the hematologic cell lineages","volume":"84","author":"Prokocimer","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib12","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood.V85.8.2013.bloodjournal8582013","article-title":"Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia","volume":"85","author":"Sill","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2010.298","article-title":"A\u00a0deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.005_bib14","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2007-07-102533","article-title":"RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL(+) leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance","volume":"111","author":"Roche-Lestienne","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","article-title":"BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros","volume":"453","author":"Mullighan","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.beha.2016.10.005_bib16","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.leu.2404227","article-title":"Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis","volume":"20","author":"Zheng","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.005_bib17","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beha.2016.10.005_bib18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJMoa040258","article-title":"Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML","volume":"351","author":"Jamieson","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.10.005_bib19","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1182\/blood-2009-03-212969","article-title":"The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data","volume":"114","author":"Oehler","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib20","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1172\/JCI41246","article-title":"Chronic myeloid leukemia: mechanisms of blastic transformation","volume":"120","author":"Perrotti","year":"2010","journal-title":"J\u00a0Clin Invest"},{"issue":"Suppl. 2","key":"10.1016\/j.beha.2016.10.005_bib21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00277-015-2325-z","article-title":"Natural course and biology of CML","volume":"94","author":"Chereda","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2016.10.005_bib22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrc799","article-title":"Oncogenic tyrosine kinases and the DNA-damage response","volume":"2","author":"Skorski","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.beha.2016.10.005_bib23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","article-title":"BCR\/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance","volume":"108","author":"Koptyra","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib24","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/blood-2004-05-1941","article-title":"BCR\/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks","volume":"104","author":"Nowicki","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib25","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood-2009-01-197186","article-title":"Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors","volume":"114","author":"Soverini","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib26","doi-asserted-by":"crossref","first-page":"24273","DOI":"10.1074\/jbc.M002094200","article-title":"The BCR\/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells","volume":"275","author":"Sattler","year":"2000","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beha.2016.10.005_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000208322","article-title":"The treatment of terminal metamorphosis of chronic granulocytic leukaemia with corticosteroids and vincristine","volume":"50","author":"Marmont","year":"1973","journal-title":"Acta Haematol"},{"key":"10.1016\/j.beha.2016.10.005_bib28","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1056\/NEJM197804132981503","article-title":"Terminal transferase as a predictor of initial responsiveness to vincristine and prednisone in blastic chronic myelogenous leukemia","volume":"298","author":"Marks","year":"1978","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.10.005_bib29","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1200\/JCO.1986.4.7.1079","article-title":"High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis","volume":"4","author":"Iacoboni","year":"1986","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.10.005_bib30","first-page":"1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-Year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.beha.2016.10.005_bib31","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.beha.2016.10.005_bib32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00277-015-2324-0","article-title":"Management of chronic myeloid leukemia in blast crisis","volume":"94","author":"Saussele","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2016.10.005_bib33","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.10.005_bib34","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib35","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood.V99.10.3547","article-title":"Imatinib mesylate (STI571) therapy for Philadelphia chromosome\u2013positive chronic myelogenous leukemia in blast phase","volume":"99","author":"Kantarjian","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib36","first-page":"1213","article-title":"Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia","volume":"88","author":"Sureda","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.10.005_bib37","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.13068","article-title":"Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up","volume":"93","author":"Palandri","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.10.005_bib38","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.005_bib39","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.10.005_bib40","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/leu.2008.221","article-title":"Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase","volume":"22","author":"Cortes","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.005_bib41","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1002\/cncr.25123","article-title":"Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily","volume":"116","author":"Saglio","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2016.10.005_bib42","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib43","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.10.005_bib44","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/leu.2011.355","article-title":"Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase","volume":"26","author":"Giles","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.005_bib45","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/cncr.22535","article-title":"Imatinib combined with mitoxantrone\/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis","volume":"109","author":"Fruehauf","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2016.10.005_bib46","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cncr.22470","article-title":"Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia","volume":"109","author":"Oki","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2016.10.005_bib47","first-page":"283","article-title":"A\u00a0pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase","volume":"48","author":"Quintas-Cardama","year":"2007","journal-title":"LeukLymphoma"},{"key":"10.1016\/j.beha.2016.10.005_bib48","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/cncr.22901","article-title":"Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib","volume":"110","author":"Cortes","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2016.10.005_bib49","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00277-010-0991-4","article-title":"Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib","volume":"89","author":"Fang","year":"2010","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2016.10.005_bib50","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/sj.leu.2404115","article-title":"High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia","volume":"20","author":"Rea","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.005_bib51","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.leukres.2010.11.004","article-title":"The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study)","volume":"35","author":"Deau","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2016.10.005_bib52","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3324\/haematol.2011.057513","article-title":"Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation","volume":"97","author":"Milojkovic","year":"2012","journal-title":"Haematol Hematol J"},{"key":"10.1016\/j.beha.2016.10.005_bib53","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cncr.28433","article-title":"HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia","volume":"120","author":"Strati","year":"2014","journal-title":"Cancer"},{"issue":"49","key":"10.1016\/j.beha.2016.10.005_bib54","first-page":"3666","article-title":"Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis","volume":"2013","author":"Ghez","year":"1990","journal-title":"Eur J cancer"},{"key":"10.1016\/j.beha.2016.10.005_bib55","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2146\/ajhp140221","article-title":"Bosutinib for the treatment of chronic myeloid leukemia","volume":"72","author":"Doan","year":"2015","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.beha.2016.10.005_bib56","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A\u00a0phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.10.005_bib57","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"Valent","year":"2015","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.beha.2016.10.005_bib58","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00277-015-2318-y","article-title":"Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"94","author":"Rea","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2016.10.005_bib59","first-page":"513","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.10.005_bib60","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","article-title":"Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV","volume":"115","author":"Saussele","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib61","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.2567.2567","article-title":"Allogeneic hematopoietic stem cell transplantation (HSCT) in the imatinib-era: update on the survival outcome following allogeneic HSCT after imatinib failure; results of the German CML study IV","volume":"124","author":"Saussele","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib62","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/bmt.2014.146","article-title":"Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis","volume":"49","author":"Jiang","year":"2014","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.beha.2016.10.005_bib63","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/leu.2015.281","article-title":"Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment","volume":"30","author":"Gratwohl","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.005_bib64","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00277-012-1650-8","article-title":"Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"92","author":"Oyekunle","year":"2013","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2016.10.005_bib65","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.beha.2009.05.002","article-title":"Current role of stem cell transplantation in chronic myeloid leukaemia","volume":"22","author":"Gratwohl","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.beha.2016.10.005_bib66","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1182\/blood-2005-05-1816","article-title":"Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"107","author":"Jabbour","year":"2006","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.beha.2016.10.005_bib67","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00277-015-2313-3","article-title":"The role of hematopoietic stem cell transplantation in chronic myeloid leukemia","volume":"94","author":"Gratwohl","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2016.10.005_bib68","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccr.2005.10.015","article-title":"The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR\/ABL-regulated SET protein","volume":"8","author":"Neviani","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.beha.2016.10.005_bib69","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1182\/blood-2010-08-304477","article-title":"Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression","volume":"117","author":"Lucas","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib70","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/leu.2016.42","article-title":"High CIP2A levels correlate with an antiapoptotic phenotype that can be overcome by targeting BCL-XL in chronic myeloid leukemia","volume":"30","author":"Lucas","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.005_bib71","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1084\/jem.20110304","article-title":"BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia","volume":"208","author":"Hurtz","year":"2011","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.beha.2016.10.005_bib72","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1182\/blood-2011-10-387381","article-title":"HIF1\u03b1 is required for survival maintenance of chronic myeloid leukemia stem cells","volume":"119","author":"Zhang","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib73","doi-asserted-by":"crossref","DOI":"10.1038\/nature07737","article-title":"Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.beha.2016.10.005_bib74","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/leu.2011.285","article-title":"Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors","volume":"26","author":"Mak","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.005_bib75","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/leu.2011.67","article-title":"The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem\/progenitor cells","volume":"25","author":"Pellicano","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.005_bib76","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1001-9294(13)60036-X","article-title":"Combination of rapamycin and imatinib in treating refractory chronic myeloid leukemia myeloid blast crisis:a case report(025B3;)","volume":"28","author":"Xie","year":"2013","journal-title":"Chin Med Sci J"},{"key":"10.1016\/j.beha.2016.10.005_bib77","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature14119","article-title":"Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation","volume":"519","author":"Pemovska","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.beha.2016.10.005_bib78","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1038\/bcj.2015.30","article-title":"Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing","volume":"5","author":"Pietarinen","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.beha.2016.10.005_bib79","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.10.005_bib80","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1182\/blood-2005-08-3320","article-title":"Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy","volume":"107","author":"Kaeda","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib81","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.beha.2016.10.005_bib82","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1007\/s00277-015-2320-4","article-title":"Discontinuation of tyrosine kinase therapy in CML","volume":"94","author":"Mahon","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2016.10.005_bib83","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","article-title":"Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score","volume":"118","author":"Hasford","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib84","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.005_bib85","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1182\/blood-2009-02-204693","article-title":"Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance","volume":"114","author":"Verma","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib86","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/sj.leu.2402813","article-title":"Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate","volume":"17","author":"Schoch","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.005_bib87","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1182\/blood-2002-09-2790","article-title":"Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy","volume":"101","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib88","series-title":"Major route additional chromosomal aberrations (ACA) precede increase of blasts in chronic myeloid leukemia (CML) independent of therapy. An analysis of CML studies III, IIIA and IV","author":"Voskanyan","year":"2016"},{"key":"10.1016\/j.beha.2016.10.005_bib89","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/leu.2009.222","article-title":"Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment","volume":"24","author":"Haferlach","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.005_bib90","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/cncr.25015","article-title":"Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy","volume":"116","author":"Verma","year":"2010","journal-title":"Cancer"},{"issue":"122","key":"10.1016\/j.beha.2016.10.005_bib91","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"2013","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.beha.2016.10.005_bib92","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00277-015-2327-x","article-title":"Response-related predictors of survival in CML","volume":"94","author":"Hanfstein","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.beha.2016.10.005_bib93","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1038\/leu.2014.153","article-title":"Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib","volume":"28","author":"Hanfstein","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.005_bib94","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib95","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1172\/JCI31095","article-title":"FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia","volume":"117","author":"Neviani","year":"2007","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beha.2016.10.005_bib96","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1182\/blood.V118.21.3757.3757","article-title":"A\u00a0novel SET antagonist (OP449) is cytotoxic to CML cells, including the highly-resistant BCR-ABLT315I mutant, and demonstrates enhanced efficacy in combination with ABL tyrosine kinase inhibitors","volume":"118","author":"Agarwal","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib97","first-page":"4539","article-title":"Dasatinib plus smoothened (SMO) inhibitor BMS-833923 in chronic myeloid leukemia (CML) with resistance or suboptimal response to a prior tyrosine kinase inhibitor (TKI): phase I study CA180323","volume":"124","author":"Shah","year":"2014","journal-title":"Blood ASH Annu Meet Abstr"},{"key":"10.1016\/j.beha.2016.10.005_bib98","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood.V118.21.1693.1693","article-title":"Combination targeted therapy to impair self-renewal capacity of human blast crisis leukemia stem cells","volume":"118","author":"Court Recart","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib99","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in\u00a0vitro and in\u00a0vivo","volume":"124","author":"Gallipoli","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.005_bib100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12935-015-0158-4","article-title":"The effect of nilotinib plus arsenic trioxide on the proliferation and differentiation of primary leukemic cells from patients with chronic myoloid leukemia in blast crisis","volume":"15","author":"Wang","year":"2015","journal-title":"Cancer Cell Int"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T22:48:43Z","timestamp":1718837323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692616300585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":100,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S1521692616300585"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2016.10.005","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of CML-blast crisis","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2016.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}